Advertisement

Current Psychiatry Reports

, 19:91 | Cite as

Marijuana Use and Organ Transplantation: a Review and Implications for Clinical Practice

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Complex Medical-Psychiatric Issues

Abstract

Purpose of Review

Physicians of all disciplines must rapidly adjust their clinical practices following the expansion of marijuana legalization across the country. Organ transplantation teams are uniquely struggling in this gray zone with eight states having passed laws explicitly banning the denial of transplant listing based on a patient’s use of medical marijuana. In this review, we examine the clinical evidence of marijuana use in transplant patients to enable psychiatric providers to meaningfully contribute to the relevant medical and psychiatric aspects of this issue in a unique patient population.

Recent Findings

There is no consensus among experts regarding marijuana use in transplantation patients. There are extant case reports of post-transplant complications attributed to marijuana use including membranous glomerulonephritis, ventricular tachycardia, and tacrolimus toxicity. However, recent studies suggest that the overall survival rates in kidney, liver, lung, and heart transplant patients using marijuana are equivalent to non-users.

Summary

Transplant teams should not de facto exclude marijuana users from transplant listing but instead holistically evaluate a patient’s candidacy, integrating meaningful medical, psychiatric, and social variables into the complex decision-making process. Psychiatric providers can play a key role in this process. Appropriate stewardship over donor organs, a limited and precious resource, will require a balance of high-clinical standards with inclusive efforts to treat as many patients as possible.

Keywords

Marijuana Cannabis Organ transplantation Transplantation Legalization Transplant psychiatry 

Notes

Acknowledgements

The editors would like to thank Dr. Kamalika Roy for taking the time to review this manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1–23.PubMedCrossRefGoogle Scholar
  2. 2.
    • Neyer J, Uberoi A, Hamilton M, Kobashigawa JA. Marijuana and listing for heart transplant: a survey of transplant providers. Circulation Heart failure. 2016;9(7):1-8. Online survey of transplant providers showing impact of marijuana use on listing for transplant. Google Scholar
  3. 3.
    Allen LA, Ambardekar AV. Hashing It Out Over Cannabis: Moving Toward a Standard Guideline on Substance Use for Cardiac Transplantation Eligibility That Includes Marijuana. Circ Heart Fail. 2016;9(7):1-3.Google Scholar
  4. 4.
    Hamadeh R, Ardehali A, Locksley RM, York MK. Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest. 1988;94(2):432–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Marks WH, Florence L, Lieberman J, Chapman P, Howard D, Roberts P, et al. Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Transplantation. 1996;61(12):1771–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Vethanayagam D, Pugsley S, Dunn E, Russell D, Kay JM, Allen C. Exogenous lipid pneumonia related to smoking weed oil following cadaveric renal transplantation. Can Respir J. 2000;7(4):338–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Ranganathan M, Skosnik PD, D’Souza DC. Marijuana and madness: associations between cannabinoids and psychosis. Biol Psychiatry. 2016;79(7):511–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117–27.PubMedCrossRefGoogle Scholar
  9. 9.
    McHugh M, McGorry P, Yung A, Lin A, Wood S, Hartmann J, et al. Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis. Psychol Med. 2017;47(4):616–26.PubMedCrossRefGoogle Scholar
  10. 10.
    Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction. 2008;103(6):969–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Lopez-Quintero C, de los Cobos JP, Hasin DS, Okuda M, Wang S, Grant BF, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend. 2011;115(1):120–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Tetrault JM, Crothers K, Moore BA, Mehra R, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med. 2007;167(3):221–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Hefner KR, Starr MJ, Curtin JJ. Altered subjective reward valuation among drug-deprived heavy marijuana users: a version to uncertainty. J Abnorm Psychol. 2016;125(1):138.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Ranney D, Acker W, Al-Holou S, Ehrlichman L, Lee D, Lewin S, et al. Marijuana use in potential liver transplant candidates. Am J Transplant. 2009;9(2):280–5. Retrospective cohort study of liver transplant patients using marijuana. PubMedCrossRefGoogle Scholar
  16. 16.
    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci. 2012;109(40):E2657–E64.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Working to Reform Marijuana Laws. In: The National Organization for the Reform of Marijuana Laws.https://norml.org/legal/legalization. Accessed 14 May 2017
  18. 18.
    Working to Reform Marijuana Laws. In: The National Organization for the Reform of Marijuana Laws.https://norml.org/legal/medical-marijuana-2. Accessed 14 May 2017.
  19. 19.
    Greenberg RL. Medical marijuana post-McIntosh. City University of New York Law Review. 2016;20(1):12.Google Scholar
  20. 20.
    Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under US law. Epilepsy Behavior: E&B. 2017;70:288-91.Google Scholar
  21. 21.
    Drug Enforcement Administration DoJ. Applications to become registered under the controlled substances act to manufacture marijuana to supply researchers in the United States. Policy Statement Fed Regist. 2016;81(156):53846.Google Scholar
  22. 22.
    Leonard K (2017) DEA chief: 'Marijuana is not medicine'. In: Washington Examiner. https://www.washingtonexaminer.com/dea-chief-marijuana-is-not-medicine/article/2624211. Accessed 20 Sep 2017.
  23. 23.
    • Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–7. Landmark review of marijuana’s impact on overall human behavior. PubMedCrossRefGoogle Scholar
  24. 24.
    ElSohly M. Potency monitoring program quarterly report no. 123—Reporting Period: 09: 16/2013–12/15/2013. Oxford, MS: University of Mississippi and National Institute for Drug Abuse; 2014.Google Scholar
  25. 25.
    ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    MacCoun RJ, Mello MM. Half-baked—the retail promotion of marijuana edibles. N Engl J Med. 2015;372(11):989–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Pierre JM. Risks of increasingly potent cannabis: the joint effects of potency and frequency. Curr Psychiatr Ther. 2017;16(2):14–20.Google Scholar
  28. 28.
    Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313(24):2491–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Friese B, Slater MD, Annechino R, Battle RS. Teen use of marijuana edibles: a focus group study of an emerging issue. J Prim Prev. 2016;37(3):303–9.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Lamy FR, Daniulaityte R, Sheth A, Nahhas RW, Martins SS, Boyer EW, et al. “Those edibles hit hard”: exploration of twitter data on cannabis edibles in the US. Drug Alcohol Depend. 2016;164:64–70.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Hancock-Allen JB, Barker L, VanDyke M, Holmes DB. Notes from the field: death following ingestion of an edible marijuana product-Colorado, March 2014. MMWR Morb Mortal Wkly Rep. 2015;64(28):771–2.PubMedCrossRefGoogle Scholar
  32. 32.
    Stogner JM, Miller BL. Assessing the dangers of “dabbing”: mere marijuana or harmful new trend? Pediatrics. 2015;136(1):1–3.PubMedCrossRefGoogle Scholar
  33. 33.
    Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav. 2014;39(10):1430–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Keller CJ, Chen EC, Brodsky K, Yoon JH. A case of butane hash oil (marijuana wax)-induced psychosis. Subst Abus. 2016;37(3):384–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Jensen G, Bertelotti R, Greenhalgh D, Palmieri T, Maguina P. Honey oil burns: a growing problem. J Burn Care Res. 2015;36(2):e34–e7.PubMedCrossRefGoogle Scholar
  36. 36.
    Winder GS, Stilger B, Ehrnstrom C, Hosanagar A. Veterans’ use of designer cathinones and cannabinoids. Federal Practioner. 2014;31(11):22–7.Google Scholar
  37. 37.
    Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21(4):320–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Loeffler G, Hurst D, Penn A, Yung K. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. armed forces. Mil Med. 2012;177(9):1041–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Devane WA, Breuer A, Sheskin T, Jaerbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem. 1992;35(11):2065–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Tofighi B, Lee JD. Internet highs—seizures after consumption of synthetic cannabinoids purchased online. J Addict Med. 2012;6(3):240–1.PubMedCrossRefGoogle Scholar
  41. 41.
    Schneir AB, Cullen J, Ly BT. “Spice” girls: synthetic cannabinoid intoxication. J Emerg Med. 2011;40(3):296–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Fattore L. Synthetic cannabinoids—further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry. 2016;79(7):539–48.PubMedCrossRefGoogle Scholar
  43. 43.
    • Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72(12):1235–42. Epidemiologic analysis of marijuana use. PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    • Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry. 2016;73(3):300–1. Epidemiologic analysis of marijuana use. PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Cerdá M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J, et al. Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatr. 2017;171(2):142–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Wall MM, Mauro C, Hasin DS, Keyes KM, Cerda M, Martins SS, et al. Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: commentary on and reanalysis of US national survey on drug use in households data 2002–2011. Int J Drug Policy. 2016;29:9–13.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    •• Greenan G, Ahmad SB, Anders MG, Leeser A, Bromberg JS, Niederhaus SV. Recreational marijuana use is not associated with worse outcomes after renal transplantation. Clin Transpl. 2016;30(10):1340–6. Retrospective cohort study of kidney transplant patients using marijuana. CrossRefGoogle Scholar
  48. 48.
    •• Nickels M, Jain A, Sharma R, Orloff M, Tsoulfas G, Kashyap R, et al. Polysubstance abuse in liver transplant patients and its impact on survival outcome. Exp Clin Transplant. 2007;5(2):680. Retrospective cohort study of liver transplant patients using marijuana. PubMedGoogle Scholar
  49. 49.
    •• Mohite PN, Zeriouh M, Sáez DG, Popov A-F, Sabashnikov A, Zych B, et al. Influence of history of cannabis smoking in selected donors on the outcomes of lung transplantation. Eur J Cardiothorac Surg. 2017;51(1):142–7. Retrospective cohort study of liver transplant donors using marijuana. PubMedCrossRefGoogle Scholar
  50. 50.
    •• Xu DS, Hartman D, Ludrosky K, Campbell J, Starling RC, Taylor DO, et al. Impact of donor high-risk social behaviors on recipient survival in cardiac transplantation. Transplantation. 2010;89(7):873–8. Retrospective cohort study of heart transplant donors using marijuana among other high-risk social behaviors. PubMedCrossRefGoogle Scholar
  51. 51.
    Hauser N, Sahai T, Richards R, Roberts T. High on cannabis and calcineurin inhibitors: a word of warning in an era of legalized marijuana. Case Reports in Transplantation. 2016;2016:1-3.Google Scholar
  52. 52.
    Munckhof W, Konstantinos A, Wamsley M, Mortlock M, Gilpin C. A cluster of tuberculosis associated with use of a marijuana water pipe. Int J Tuberc Lung Dis. 2003;7(9):860–5.PubMedGoogle Scholar
  53. 53.
    Oeltmann JE, Oren E, Haddad MB, Lake LK, Harrington TA, Ijaz K, et al. Tuberculosis outbreak in marijuana users, Seattle, Washington, 2004. Emerg Infect Dis. 2006;12(7):1156.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Lázaro IJS, Bonet LA, Sancho-Tello MJ, Martínez-Dolz L. Ventricular tachycardia due to marijuana use in a heart transplant patient. Revista Española de Cardiología (English Edition). 2009;62(4):459–61.Google Scholar
  55. 55.
    Bohatyrewicz M, Urasinska E, Rozanski J, Ciechanowski K, editors. Membranous glomerulonephritis may be associated with heavy marijuana abuse. Transplantation Proceedings. Elsevier; 2007.Google Scholar
  56. 56.
    Catalano C, Seck S, Enia G. Severe hyponatraemia during sepsis and marijuana addiction. BMJ Case Rep. 2011;2011:1-2.Google Scholar
  57. 57.
    Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J. 2013;6(3):330–3.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):1566–70.Google Scholar
  59. 59.
    Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid Hyperemesis: A Case Series of 98 Patients. Mayo Clin Proc 2012;87(2):114–9.Google Scholar
  60. 60.
    Hézode C, Roudot‐Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42(1):63–71.Google Scholar
  61. 61.
    Blanco C, Hasin DS, Wall MM, Flórez-Salamanca L, Hoertel N, Wang S, et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA Psychiatry. 2016;73(4):388–95.PubMedCrossRefGoogle Scholar
  62. 62.
    Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition—a systematic review. Biol Psychiatry. 2016;79(7):557–67.PubMedCrossRefGoogle Scholar
  63. 63.
    Levenson JL. The American psychiatric publishing textbook of psychosomatic medicine: psychiatric care of the medically ill. Arlington: American Psychiatric Pub; 2011.Google Scholar
  64. 64.
    Stanslowsky N, Jahn K, Venneri A, Naujock M, Haase A, Martin U, et al. Functional effects of cannabinoids during dopaminergic specification of human neural precursors derived from induced pluripotent stem cells. Addict Biol. 2016;22(5):1329–42.PubMedCrossRefGoogle Scholar
  65. 65.
    Gaffuri A-L, Ladarre D, Lenkei Z. Type-1 cannabinoid receptor signaling in neuronal development. Pharmacology. 2012;90(1–2):19–39.PubMedCrossRefGoogle Scholar
  66. 66.
    Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195–8.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Chiou L-C, Hu SS-J, Ho Y-C. Targeting the cannabinoid system for pain relief? Acta Anaesthesiol Taiwanica. 2013;51(4):161–70.CrossRefGoogle Scholar
  68. 68.
    Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. J Am Soc Anesthesiologists. 2007;107(5):785–96.Google Scholar
  69. 69.
    Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506–21.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136–48.PubMedCrossRefGoogle Scholar
  71. 71.
    Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333–49.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013;38(10):1984–92.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30(3):271–80.PubMedCrossRefGoogle Scholar
  74. 74.
    Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293(16):795–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother Res. 2013;27(5):633–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–7.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Centonze D, Mori F, Koch G, Buttari F, Codecà C, Rossi S, et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci. 2009;30(6):531.PubMedCrossRefGoogle Scholar
  78. 78.
    Collin C, Davies P, Mutiboko I, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, et al. Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant. 2015;21(10):1770–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Hochhauser E, Lahat E, Sultan M, Pappo O, Waldman M, Sarne Y, et al. Ultra low dose delta 9-tetrahydrocannabinol protects mouse liver from ischemia reperfusion injury. Cell Physiol Biochem. 2015;36(5):1971–81.PubMedCrossRefGoogle Scholar
  81. 81.
    Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50(10):1368–81.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.PubMedCrossRefGoogle Scholar
  83. 83.
    Owen KP, Sutter ME, Albertson TE. Marijuana: respiratory tract effects. Clin Rev Allergy Immunol. 2014;46(1):65–81.PubMedCrossRefGoogle Scholar
  84. 84.
    Brunet L, Moodie EE, Rollet K, et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013;57(5):663–70.Google Scholar
  85. 85.
    Panlilio LV, Zanettini C, Barnes C, Solinas M, Goldberg SR. Prior exposure to THC increases the addictive effects of nicotine in rats. Neuropsychopharmacology. 2013;38(7):1198–208.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Levine A, Huang Y, Drisaldi B, Griffin EA, Pollak DD, Xu S, et al. Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med. 2011;3(107):107ra9-ra9.CrossRefGoogle Scholar
  87. 87.
    Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry. 2004;56(2):86–94.PubMedCrossRefGoogle Scholar
  88. 88.
    Emre S, Genyk Y, Schluger LK, Fishbein TM, Guy SR, Sheiner PA, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int. 2000;13(1):73–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13(5):313–26.PubMedCrossRefGoogle Scholar
  90. 90.
    Lorenzetti V, Solowij N, Yücel M. The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry. 2016;79(7):e17–31.PubMedCrossRefGoogle Scholar
  91. 91.
    Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.PubMedCrossRefGoogle Scholar
  92. 92.
    Meng H, Hanlon JG, Katznelson R, Ghanekar A, McGilvray I, Clarke H. The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report. Can J Anesth/Journal canadien d'anesthésie. 2016;63(3):307–10.PubMedCrossRefGoogle Scholar
  93. 93.
    D’Souza G, Matson P, Grady CD, Nahvi S, Merenstein D, Weber K, et al. Medicinal and recreational marijuana use among HIV-infected women in the Women’s Interagency HIV cohort (WIHS), 1994–2010. J Acquir Immune Defic Syndr. 2012;61(5):618.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. The Cochrane Library. 2013(4):1-45.Google Scholar
  95. 95.
    Hill T, Cascio MG, Romano B, Duncan M, Pertwee R, Williams C, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679–92.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Basu P, Aloysius M, Shah N, Brown R Jr. Review article: the endocannabinoid system in liver disease, a potential therapeutic target. Aliment Pharmacol Ther. 2014;39(8):790–801.PubMedCrossRefGoogle Scholar
  97. 97.
    Baumrucker S, Mingle P, Harrington D, Stolick M, Carter GT, Oertli KA. Medical marijuana and organ transplantation: drug of abuse, or medical necessity? Am J Hosp Palliat Med®. 2011;28(2):130–4.CrossRefGoogle Scholar
  98. 98.
    Network OPaT. OPTN: organ procurement and transplantation network—OPTN. 2017. https://optn.transplant.hrsa.gov/. Accessed 11 June 2017.

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.University of Michigan Department of PsychiatryAnn ArborUSA

Personalised recommendations